Wei is Founding Partner of Fortunatus Capital, a life sciences venture capital fund based in Boston investing globally.
Previously, Wei was advising investors and innovative companies in the US and Asia. He was President and CEO of an early stage biotech focusing on novel predictive models for cancer and autoimmune diseases drug development. He also led corporate development at a commercial stage genetic testing company.
Wei was a key member of the healthcare team at Safeguard Scientifics, an NYSE listed investment firm with 60 years of history. Prior to Safeguard, Wei worked part-time at BioAdvance, a state initiative committed to funding early-stage life sciences companies, while he was pursuing his MBA at Wharton. Wei had also worked part-time or consulted for several funds in the US and Asia when he was in business school.
Before Wharton, Wei was a Department Head at ImmunoGen, where he built a new division in cancer drug development and contributed to ImmunoGen?s partnerships with leading pharmaceutical and biotech companies. Wei was a staff scientist at Genetics Institute, a division of Wyeth, where he developed biologics in several therapeutic areas. He finished his postdoctoral research in combinatorial chemistry at Sphinx Pharmaceuticals/Eli Lilly. Wei is an inventor of over a dozen issued and pending patents and author of 17 scientific publications.
Education, Personal, and Fellowship
Wei holds an MBA from the Wharton School, where he received a fellowship in healthcare entrepreneurship. Wei also earned a BS in chemistry, with Honors, from Nanjing University, and MA and PhD degrees from Boston University.
Wei is a member of Fellows Class 14, and served his fellowship under the mentorship of Jim Datin at Safeguard Scientifics.